About Mitochondrial glutathione transporter SLC25A39
Mitochondrial glutathione transporter SLC25A39 (SLC25A39) is a protein
from Homo sapiens identified by UniProt accession
Q9BZJ4, 359 residues long.
MolForge cross-references it against 0 known binders and
50 disease associations.
Target properties
| Protein name | Mitochondrial glutathione transporter SLC25A39 |
| UniProt accession | Q9BZJ4 |
| Gene | SLC25A39 |
| Organism | Homo sapiens |
| Length | 359 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (50)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.34
- eosinophil count · score 0.23
- monocyte percentage of leukocytes · score 0.21
- granulocyte percentage of myeloid white cells · score 0.10
- platelet-to-lymphocyte ratio · score 0.09
- reticulocyte count · score 0.06
- mean corpuscular hemoglobin concentration · score 0.06
- Red cell distribution width · score 0.06
- mean corpuscular hemoglobin · score 0.06
- reticulocyte measurement · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BZJ4-F1 | alphafold | PREDICTED | 73.91 | — |
Amino-acid sequence (359 residues)
MADQDPAGIS PLQQMVASGT GAVVTSLFMT PLDVVKVRLQ SQRPSMASEL MPSSRLWSLS YTKLPSSLQS TGKCLLYCNG VLEPLYLCPN GARCATWFQD PTRFTGTMDA FVKIVRHEGT RTLWSGLPAT LVMTVPATAI YFTAYDQLKA FLCGRALTSD LYAPMVAGAL ARLGTVTVIS PLELMRTKLQ AQHVSYRELG ACVRTAVAQG GWRSLWLGWG PTALRDVPFS ALYWFNYELV KSWLNGFRPK DQTSVGMSFV AGGISGTVAA VLTLPFDVVK TQRQVALGAM EAVRVNPLHV DSTWLLLRRI RAESGTKGLF AGFLPRIIKA APSCAIMIST YEFGKSFFQR LNQDRLLGG
Explore Mitochondrial glutathione transporter SLC25A39 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets